Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 10:25:00 23/01/2026 pm IST			5-day change	1st Jan Change
3.735 ^EUR	+2.33%		+7.02%	-10.97%

22/01	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading	MT
14/01	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT

Cellectis Names Bing Wang Finance Chief

Published on 02/11/2022 at 03:36 pm IST - Modified on 02/11/2022 at 03:37 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

22/01	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading	MT
14/01	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
13/01	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading	MT
30/12	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
29/12	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT
26/12	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week	MT
23/12	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
22/12	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
19/12	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Slightly Higher for Week	MT
18/12	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading	MT
16/12	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
16/12	Cellectis shares fall after arbitration in dispute with Servier
16/12	Cellectis announces arbitral decision in dispute with Servier	RE
15/12	Cellectis S.A. - Analyst/Investor Day
12/12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
11/12	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
10/12	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT
09/12	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
08/12	Encouraging Phase 1 Data for Cellectis in Non-Hodgkin Lymphoma
08/12	Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL	CI
01/12	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
26/11	European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading	MT
24/11	European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading	MT
21/11	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week	MT
20/11	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

219

Sector

Biotechnology & Medical Research

Calendar

29/01 - Allinvest Securities Biomed Forum

More about the company